62921-33-9

Usage

Uses

Used in Pharmaceutical Industry:
(14E,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[(methylamino)methyl]-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate is used as a potential pharmaceutical candidate for various applications due to its complex structure and potential biological activity. Its multiple hydroxyl and methoxy groups, as well as the presence of a naphtho[2,1-b]furan ring and a pentadeca[1,11,13]trienoimino group, may contribute to its potential therapeutic effects. Further research and development are needed to fully explore its potential uses and benefits in the pharmaceutical industry.

Upstream product

• 13292-22-3 3-formylrifamycin SV 
• 74-89-5 methylamine 

Downstream Products

• 62921-36-2 N,15-didehydro-15-deoxo-3,15-epi(methano(methylimino))rifamycin SV 
• 62921-38-4 Pyrimidinorifamycin 5 
• 62921-35-1 Chinon 4 

Relevant academic research and scientific papers

N,15-Didehydro-15-deoxo-3,15-epi(methano(alkylimino))rifamycins and antimicrobial compositions and methods employing them

N,15-Didehydro-15-deoxo-3,15-epi(methano(alkylimino))rifamycins which can exist in either the quinone or hydroquinone form, are prepared from the corresponding Mannich base derivatives by an acid-catalyzed dehydration reaction.

3-N-substituted aminomethyl derivatives of rifamycin SV. A convenient method of synthesis, cyclization of certain derivatives, and anticellular and antiviral activities of several derivatives

A new synthesis of Mannich bases of rifamycin SV using the Borch procedure with rifaldehyde is described. This new synthesis offers two advantages over the previously published method. It provides a route to monoalkyl-aminomethylrifamycins (1e-h) and to unsubstituted aminomethylrifamycins that were not accessible by the old procedure. The new method also offers a preparative route to Mannich bases 1a and 1b which were needed in multigram quantities for biological testing. In addition, the cyclization of certain of the monoalkylaminomethylrifamycins to the novel N,15 didehydro 15 deoxo 3,15 epi[methano(alkylimino)]rifamycin SV derivatives is described. The anticellular and antiviral effects of representatives of both series of compounds against cultured mouse cells and murine oncornavirus are discussed.